|  |
| --- |
| Table J-31. Studies evaluating independent predictive value of BNP for the outcome of composite of all-cause mortality and all-cause morbidity in patients with stable heart failure  |
| **Author****Year** | **Study Design****Population** | **n****Mean Age (SD)****% male** | **BNP Levels (pg/mL)** | **Prognostic Markers** | **Followup****Outcomes****(#events, #risk)** | **Model** | **Adjusted/Non-****adjusted****Covariates** | **Measure(s) of****Risk****(95% CI,)** |
| Bermingham872011 | CohortNon-acute HF patients attending disease management program  | n=1,294mean age:70.6y(11.5)64.0% male | ADM mean:326(138-680)\*\*D/C mean: NRCutpoint: NR | lnBNP, beta2-agonist, age, diastolic BP, smoking status, MI and angina, beta-blocker use, anti-platelet use | 33mComposite (all-cause hospitalization & mortality)(653, 1,294) | Multivariable cox proportional hazard regression | beta2-agonist, age, diastolic BP, smoking status, MI and angina, beta-blocker use, anti-platelet use | HR=1.28(1.17-1.41) |

**Abbreviations:** BNP=B-type natriuretic peptide; BP=blood pressure; 95% CI,=confidence interval; HR=hazard ratio; ln=natural log; MI=myocardial infarction; n=number; pg/mL=picograms per milliliter; SD=standard deviation; y=year(s)